Study identification

EU PAS number

EUPAS1000000480

Study ID

1000000480

Official title and acronym

A Study to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 60 Years or Above (Complementary Study to DAN-RSV)

DARWIN EU® study

No

Study countries

Denmark

Study description

The primary objective is to evaluate Abrysvo® vaccine effectiveness (VE) against hospitalization for RSV-related respiratory tract disease in adults aged 60 and older stratified by immunocompromised status.

Study status

Planned
Research institutions and networks

Institutions

Copenhagen University Hospital – Herlev and Gentofte

Contact details

Tor Biering-Sorenson

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:

Study start date

Planned:

Data analysis start date

Planned:

Date of interim report, if expected

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable